Diabetes is a global health emergency projected to affect 642 million people by 2040. Type 2 diabetes (T2D) represents 90% of diabetes cases and is associated with a range of cardiovascular (CV) risk factors that are more than double the incidence of CV disease and significantly increase mortality rates. Diabetes treatments have typically focused on improving glycemic control but their effect on CV outcomes has remained uncertain. In 2008, the US Food and Drug Administration (FDA) looked to address this knowledge gap and mandated CV outcome trials (CVOTs) for all new antidiabetic therapies. In 2015, EMPA-REG OUTCOME® became the first CVOT to present results for a sodium/glucose cotransporter 2 (SGLT2; also known as SLC5A2) inhibitor, empagliflozin. Subsequently, a regional meeting of the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D) brought together a respected faculty of international experts and 150 physicians from 14 countries to discuss the current unmet medical needs of patients with T2D, the results from the EMPA-REG OUTCOME study and the implications of these results for clinical practice. This article summarizes the current scientific evidence and the discussions that took place at the ACROSS T2D regional meeting, which was held in Vienna, Austria, on May 30, 2016.

1st Faculty of Medicine Charles University Prague Czech Republic

1st Medical Department Hanusch Krankenhaus Vienna Austria

Cardiovascular Division Heart Institute Hadassah Hebrew University Medical Center Jerusalem Israel

Department of Medicine Rudolfstiftung Hospital Vienna Austria

Department of Medicine University Hospital Würzburg Germany

Richford Gate Medical Practice London UK

Zobrazit více v PubMed

International Diabetes Federation [webpage on the Internet] IDF Diabetes Atlas. 7th ed. Brussels: The Federation; 2015. [Accessed October 17, 2016]. Available from: http://www.Diabetesatlas.org/Resources/2015-Atlas.html.

Emerging Risk Factors Collaboration. Seshasai SRK, Kaptoge S, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–841. PubMed PMC

Lau DCW, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005;288(5):H2031–H2041. PubMed

Emerging Risk Factors Collaboration. Di Angelantonio E, Kaptoge S, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314(1):52–60. PubMed PMC

Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559. PubMed PMC

Advance Collaborative Group. Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. PubMed

UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352(9131):837–853. PubMed

Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139. PubMed

Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383(9933):2008–2017. PubMed

Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol. 2016;15(1):37. PubMed PMC

Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434–444. PubMed

World Heart Federation [webpage on the Internet] Cardiovascular Disease Risk Factors – Diabetes. World Heart Federation; [Accessed October 17, 2016]. Available from: http://www.World-Heart-Federation.org/Cardiovascular-Health/Cardiovascular-Disease-Risk-Factors/Diabetes/

Jeerakathil T, Johnson JA, Simpson SH, Majumdar SR. Short-term risk for stroke is doubled in persons with newly treated type 2 diabetes compared with persons without diabetes. Stroke. 2007;38(6):1739–1743. PubMed

Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care. 2013;36(8):2271–2279. PubMed PMC

American Diabetes Association Standards of medical care in diabetes – 2015. Diabetes Care. 2015;38(suppl 1):S1–S99. PubMed

Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315–2381. PubMed PMC

Collaborators CTTC. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–125. PubMed

Blood Pressure Lowering Treatment Trialists’ Collaboration. Sundström J, Arima H, et al. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384(9943):591–598. PubMed

Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603–615. PubMed

Control Group. Turnbull FM, Abraira C, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288–2298. PubMed

Bergenstal RM, Bailey CJ, Kendall DM. Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Am J Med. 2010;123(4):374.e9–374.e18. PubMed

Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12(2):90–100. PubMed PMC

AACEACE [webpage on the Internet] Comprehensive Type 2 Diabetes Management Algorithm. AACEACE; [Accessed October 17, 2016]. Available from: https://www.aace.com/publications/algorithm.

Center for Drug Evaluation and Research (CDER) Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes [Guidance for Industry] Silver Spring, MD: Center for Drug Evaluation and Research (CDER); 2008. [Accessed October 17, 2016]. Available from: http://www.Fda.Gov/Downloads/Drugs/Guidancecompli-anceregulatoryinformation/Guidances/Ucm071627.pdf.

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. PubMed

Gaede P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591. PubMed

Hirshberg B, Katz A. Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. Diabetes Care. 2013;36(suppl 2):S253–S258. PubMed PMC

Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180–1188. PubMed

Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011;342:d1309–d1309. PubMed PMC

European Medicines Agency . Guideline on Clinical Investigation of Medicinal Products in the Treatment or Prevention of Diabetes Mellitus. London: Committee for Medicinal Products for Human Use (CHMP); 2012. [Accessed October 17, 2016]. CPMP/EWP/1080/00. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf.

Geiger MJ, Mehta C, Rick Turner J, et al. Clinical development approaches and statistical methodologies to prospectively assess the cardiovascular risk of new antidiabetic therapies for type 2 diabetes. Ther Innov Regul Sci. 2015;49(1):50–64. PubMed

Johansen OE. Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach. World J Diab. 2015;6(9):1092–1096. PubMed PMC

Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. PubMed

White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. PubMed

Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. PubMed

US Food and Drug Administration . Diabetes Medications Containing Saxagliptin and Alogliptin: Drug Safety Communication – Risk of Heart Failure. Silver Spring, MD: Safety Information and Adverse Event Reporting Program; 2016. [Accessed May 5, 2016]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm.

Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257. PubMed

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. PubMed PMC

Tucker ME. Top-Line Data Show CV Benefit for Liraglutide in Type 2 Diabetes. Medscape; 2016. [Accessed May 5, 2016]. webpage on the Internet. Available from: http://www.medscape.com/viewarticle/859905.

Hach T, Gerich J, Salsali A, et al. Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal phase III trials. Diabetol Stoffwechsel. 2014;9(suppl):01.

Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37(19):1526–1534. PubMed PMC

Wanner C. The American College of Cardiology Meeting 2016 (ACC.16) Oral Presentation; Chicago, IL: 2016.

Cherney DZI, Perkins BA, Soleymanlou N, et al. The renal hemodynamic effect of SGLT2 inhibition in patients with type 1 diabetes. Circulation. 2014;129(5):587–597. PubMed

Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME Study. Diabetes Care. 2016;39(5):717–725. PubMed PMC

Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164–176. PubMed

Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869. PubMed

Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860. PubMed

Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334. PubMed

European Medicines Agency . Jardiance Summary of Product Characteristics. London: European Medicines Agency; 2016. [Accessed June 14, 2016]. EMEA/H/C/002677. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors__20/European_Commission_final_decision/WC500206515.pdf.

US Food and Drug Administration [webpage on the Internet] Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR): Drug Safety Communication – Strengthened Kidney Warnings [Safety Alert] Silver Spring, MD: Safety Information and Adverse Event Reporting Program; 2016. [Accessed June 15, 2016]. Available from: http://www.Fda.Gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm506554.htm.

Watts NB, Bilezikian JP, Usiskin K, et al. CANVAS – CANagliflozin cardiovascular Assessment Study. NCT01032629. J Clin Endocrinol Metab. 2016;101(1):157–166. PubMed PMC

AstraZeneca Multicentre Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58) [Accessed October 17, 2016]. Available from: https://clinicaltrials.gov/ct2/show/NCT01730534?term=NCT01730534&rank=1. NLM identifier: NCT01730534.

Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–1380. PubMed PMC

US Food and Drug Administration . NDA 204042: Invokana (Canagliflozin) Tablets [Briefing Document] Silver Spring, MD: Endocrinologic and Metabolic Drugs Advisory Committee; 2013. [Accessed May 6, 2016]. Available from: http://www.Fda.Gov/Downloads/%20AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/%20EndocrinologicandMetabolicDrugsAdvisory-Committee/UCM334550.pdf.

Dziuba J, Alperin P, Racketa J, et al. Modeling effects of SGLT – 2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes Metab. 2014;16(7):628–635. PubMed

Gilbert RE, Krum H. Heart failure in diabetes: effects of antihyperglycaemic drug therapy. Lancet. 2015;385(9982):2107–2117. PubMed

Dicker D. DPP-4 inhibitors. Diabetes Care. 2011;34(suppl 2):S276–S278. PubMed PMC

Centers for Disease Control and Prevention . National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. [Accessed October 17, 2016]. Chap. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589. PubMed

Sha S, Polidori D, Farrell K, et al. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Diabetes Obes Metab. 2015;17(2):188–197. PubMed PMC

Munir KM, Davis SN. Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes. Clin Pharmacol. 2016;8:19–34. PubMed PMC

US National Institutes of Health Clinical trials. [Accessed October 17, 2016]. Available from. https://clinicaltrials.gov.

Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)

Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)